Resveratrol

MND combines proprietary resveratrol-based platform and NovaSOL® Curcumin to enhance cognitive performance and support neuroprotective health Jupiter, Florida, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today introduced Nugevia™ MND, a scientifically formulated supplement designed to protect and enhance cognitive function and support overall brain health. MND addresses the surging consumer demand for clinically validated cognitive wellness solutions, opening up significant market opportunities in the rapidly growing $8 trillion longevity and wellness markets. Innovative CNS Science, Dual-Purpose Potential Nugevia MND uniquely combines Jupiter’s proprietary JOTROL™ resveratrol technology—demonstrated to significantly improve bioavailability and central nervous system penetration—with NovaSOL® Curcumin, a highly bioavailable curcumin formulation proven effective in supporting cognitive resilience and neuroprotection. This innovative pairing targets multiple neuroprotective pathways, including reducing oxidative stress, inflammation, and supporting synaptic plasticity, thereby promoting enhanced cognitive health. "We’ve worked extensively on our third, and in my opinion the most important, product in the Nugevia™ launch. It is my pleasure to introduce MND to the healthspan and longevity community,” stated Christer Rosén, Chairman and CEO of Jupiter Neurosciences. “My mother passed away from Alzheimer’s Disease making this particular product one that holds a deep sense of obligation and importance to me. Additionally, Jupiter’s former CFO ultimately lost his fight to Parkinson’s Disease. This is personal, this is important and based on our JOTROL pharmaceutical pre-clinical and clinical date we are here to bring what we believe is the best cognition product to the market.” “The introduction of Nugevia MND represents a strategic step in leveraging our CNS therapeutic expertise within the consumer health market,” added Rosén. “Importantly, learnings from consumer use of MND, combined with biomarker data anticipated from our upcoming Phase II Parkinson’s disease trial, will provide valuable insights to inform our future cognitive health programs. What is the purpose of all the new ways with early detection of these progressive diseases if there is no good way to prevent them, stop them, or significantly slow them down? We are optimistic that our clinical studies will back up my belief that we have again cracked the code and MND is the solution.” Strategic Insight, Expanded Potential Nugevia MND is poised to generate high-margin revenue by targeting adults seeking to maintain and enhance cognitive performance, particularly amidst aging populations increasingly impacted by cognitive decline. The product also strategically complements Jupiter’s therapeutic pipeline, creating synergies between consumer and pharmaceutical segments. Key scientifically supported benefits of Nugevia MND include: Enhanced memory, clarity, and executive functionReduction in neuroinflammation and oxidative stressSupport for mitochondrial function in brain cellsPotential protective effects against age-related cognitive decline "MND not only reinforces our dual-path business strategy but also provides an immediate opportunity for revenue growth and meaningful data collection," continued Rosén. "Investors can be excited about the implications of a consumer product directly supporting our pharmaceutical development pipeline." Nugevia MND will be commercially available through direct-to-consumer e-commerce platforms starting Fall 2025 as a convenient two-capsule daily regimen. A digital press kit, including high-resolution product imagery and key brand information, is available at https://ir.jupiterneurosciences.com/. About Jupiter Neurosciences, Inc. Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia™ product line. Both efforts are powered by JOTROL™, Jupiter’s proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company’s prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson’s disease, includeing indications such as Alzheimer’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com. About JOTROL Resveratrol is one of the world’s most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication. Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL™ achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer’s Disease trial, and Yui et al., Friedreich’s Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL™ trials, were published in the Journal of Alzheimer’s Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL™ toward a Phase IIa trial in Parkinson’s Disease. In addition to its therapeutic applications, JOTROL™ serves as the foundation for Jupiter’s Nugevia™ consumer supplement line. By leveraging the same clinically validated delivery technology, Nugevia™ introduces pharmaceutical-grade bioavailability into the wellness space, offering targeted support for cognitive health, skin vitality, and cellular energy. FORWARD-LOOKING STATEMENTS Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations, including the Company’s ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Contact: Dave GentryRedChip Companies, Inc.1-407-644-42561-800-RED-CHIP (733-2447)JUNS@redchip.com

临床试验资讯研究交流群（点击） 恶性肿瘤治疗还是要看免疫治疗，而不是每一个患者都能从PD-1抑制剂获益，最近兴起的肿瘤浸润淋巴细胞治疗（TILS），以及癌症治疗疫苗让大家重新燃起对肿瘤治疗的期望。癌度将最近刊登的一篇文献编译一下，看看目前对于乳腺癌来说，最近的癌症治疗疫苗有什么临床研究，治疗的效果和预期是什么？ 本文参考文献刊例示意图 一、为什么晚期乳腺癌患者要使用“疫苗”的治疗？ 对于乳腺癌来说，常规疗法（外科手术、放化疗、内分泌药物、靶向药和PD-1抑制剂等）可明显提高局限期乳腺癌患者的预后，但对于复发或转移性乳腺癌来说仍不够让人满意。今天我们癌度给大家着重接受癌症治疗疫苗，癌症治疗疫苗的目的在于活化或使免疫系统对特定的肿瘤抗原进行长期的识别和杀灭，所以理论上： 由于肿瘤细胞有与正常细胞不一样的特别抗原，癌症治疗疫苗可以增强免疫细胞对特定肿瘤抗原的免疫记忆； 联合其他免疫治疗药物，如PD-1/PD-L1抑制剂等，可打破肿瘤的免疫耐受； 癌症治疗疫苗属于免疫治疗，患者治疗的总体是耐受的，因此使用癌症治疗疫苗可以实现持久的病情控制。 所以，很多临床研究集中在针对已经发生转移和复发的晚期乳腺癌的治疗上，对于这部分患者使用癌症治疗疫苗能不能让患者获益。 图片来自：摄图网 二、目前的临床试验告诉了我们什么？ 癌度今天给大家介绍的内容，属于一项包括了19项临床试验，747例晚期/转移性乳腺癌综合分析，研究的结果如下： ① 目前的乳腺癌治疗疫苗的临床研究主要集中在早期（一期或二期），几乎没有三期随机对照的临床试验。 ② 临床试验主要采用开放标签、单臂或小样本的随机对照临床试验，主要探索使用癌症治疗疫苗之后的患者体内的一些免疫指标，以及对患者生存时间的改善。 ③ 疫苗的种类多样，包括肽疫苗、树突状细胞疫苗、全细胞/细胞裂解物疫苗、病毒载体疫苗及糖类疫苗等。在不同的癌症治疗疫苗，自然相关的免疫学指标和临床指标存在很大的差别。所以也没办法说谁更好。 ④ 大部分临床试验均能诱发出明显的 免疫T细胞或抗体的应答，患者体内出现免疫反应率的范围为44%~100%。 ⑤ 少数临床研究显示了一些喜人的趋势，如癌症疫苗与化疗、曲妥珠单抗或免疫检查点抑制剂联合可以显著提高疾病控制率，延长无进展生存期。 ⑥ 大多数癌症疫苗的副反应以注射部位反应、发热和乏力为主（1-2级）；整体的耐受性较好，因癌症疫苗而停药的情况较少。 总结一下， 疫苗的种类很多，所以结果无可比性，初步结果显示有希望，但临床试验证据不够充分，需要大型三期临床试验验证。 来自：摄图网 三、目前19项临床试验给到的启示 癌症治疗疫苗大部分是安全的，并且能够引起免疫应答，但是“激发免疫”并不总是意味着“使肿瘤消失或存活时间更长”。目前看总体获益的病人不是很多。 1、哪些患者最有可能从中获益？ 现有研究结果表明，部分亚型（例如HER2阳性乳腺癌、特定免疫微环境）使用癌症疫苗的治疗效果更佳，但缺乏统一的标准筛选谁最可能受益。  2、什么时候可以考虑癌症疫苗？ 肿瘤治疗疫苗还在临床试验阶段。对于晚期乳腺癌病人来说，参加就要选择规范化的临床试验，着重看癌症治疗疫苗的治疗机制，不是每一个癌症治疗疫苗的临床试验都值得参加。  3、未来的治疗方向很明确 开展更多规模的三期 临床试验，将癌症治疗疫苗与其他药物联合，如免疫检查点抑制剂，靶向药或小剂量化疗。更加个性化的癌症治疗疫苗可能会更好，如果基于肿瘤基因突变设置的mRNA治疗疫苗。 四、耐心地等待，癌症治疗疫苗来证实自己 癌症疫苗是一种极具吸引力的免疫疗法：它能激发患者身体的免疫系统对癌细胞进行长期的免疫监视。目前的研究结果表明该方法是有效的和安全的，但是还没有大型三期临床试验证实有效性，或直接批准为临床用药。但是对于所有治疗方法用过之后的患者，参加癌症疫苗联合其他药物的组合用药临床试验是值得的。也欢迎大家联系癌度参加筛选适合您的临床试验！ 关注癌度，了解全球肿瘤诊疗的最新进展！ （咨询癌度请扫描下面图片二维码） 参考文献： Anna Charalampopoulou, et al., A systematic review of the efficacy of cancer vaccines in advanced breast cancer, breast cancer,2025.  往期推荐  体内建造“抗癌兵工厂”：科学家成功改造干细胞，源源不断生成抗癌斗士 别再误解双抗了！常见误区 “扫雷”+答疑指南，肺癌患者必看 解锁大自然的抗癌“工具包”，绿茶、白藜芦醇、红酒和姜黄皆入选, 一文解读它们如何辅助癌症治疗？ “从无到有”，常规基因检测没有任何突变，换用RNA测序能找出87%的突变！